Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

A small study confirms observations what users have observed: the medications reduce their cravings for alcohol.

Amycretin is a GLP-1 agonist, but it also mimics ... the two top-selling weight loss drugs. In a 72-week study, Zepbound's mean weight loss was 20.2%, while Wegovy's was 13.7%.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is primarily ...

The first clinical trial of its kind found the weekly semaglutide jab cuts the amount people drink in one day by 40 per cent ...

Yet another study is supporting the notion that the blockbuster GLP-1 drug Ozempic can help problems drinkers curb their ...

Looking for weight loss options? GLP-1 agonist ... In a 68-week clinical trial involving 1,961 adults with obesity or weight-related conditions, those who took Wegovy lost an average of 35 ...